Aduro与强生签订了第二份癌症免疫疗法研究协议

Aduro与强生签订了第二份癌症免疫疗法研究协议

                               
登录/注册后可看大图

  

                               
登录/注册后可看大图

发布日期：2014-10-18  来源：生物谷  

位于加利福尼亚州伯克利的生物医药公司Aduro公司最近与强生公司签订了第二份癌症研究协议，合作进行癌症免疫疗法研究。

                               
登录/注册后可看大图

                               
登录/注册后可看大图

这份协议价值8亿1千7百万美元。此次签订的这份协议中包含了一系列的里程资金。Aduro公司将与位于湾区的强生创新中心合作，开发包括肺癌等多种癌症在内的抗癌药物。Aduro公司将利用其独有的技术平台为强生公司筛选潜在的癌症免疫疗法方案。

今年以来，癌症免疫疗法已经成为各大生物医药巨头的研究热点，此前Aduro公司就以引入一种研发失败的癌症疫苗GVAX作为癌症联合治疗的一种组分而受到了业界的广泛关注。而强生公司也希望在这一领域进一步巩固自己的地位，而在癌症免疫疗法领域拥有雄厚研究基础的Aduro公司也成为了强生公司的理想合作对象。Aduro公司是极少数在癌症研发领域取得重大成就的小型生物医药公司，旗下开发的相关药物获得了FDA的突破性药物疗法认证。

最近强生公司在癌症研发领域可谓是动作频频，早在今年五月份，强生公司就签订了一份价值3亿6千万美元的研究协议，开发治疗胰腺癌药物。同时，强生公司又投入约5500万美元招募了超过2000名患者进行癌症药物CRS-207的研究。

Aduro公司总裁兼CEO Stephen Isaacs对这次合作充满信心，并表示公司在未来将继续专注于包括胰腺癌、间皮瘤和恶性胶质瘤等肿瘤在内的癌症免疫疗法的研究。

详细英文报道：

A banner year for Berkeley, CA-based Aduro just got better. The biotech has inked its second licensing pact of the year with Johnson & Johnson ($JNJ), which kicked in a $30 million upfront and boosted its total milestone package to the $1 billion-plus category.

With the J&J Innovation Center in the Bay Area leading the way, the pharma giant grabbed rights to new product candidates for lung and other types of cancer, convinced that Aduro's platform tech holds great promise for beefing up its oncology pipeline. J&J's $817 million deal includes potential milestones for successful development efforts as it hitched a ride on a tech platform focused on the ability of engineered Listeria monocytogenes strains to kick up an immune response against cancer.

Immunotherapies have emerged as the single hottest R&D strategy of the year. And Aduro, a 2014 Fierce 15 company, has attracted close attention for its use of a failed cancer vaccine--GVAX--as part of a combo approach to direct an attack on cancer. J&J is known for making ambitious plays in this field when it finds a new technology that it likes. And the pharma giant appears to be all in on Aduro.

Back in May J&J signed a $365 million deal covering prostate cancer, a major focus for J&J. The pharma giant also kicked in for a recent $55 million venture round to fund an expanded Phase IIb trial of its cancer combo, which is enrolling about 240 patients into three treatment arms: one receiving the combination treatment, one taking CRS-207 alone and another on standard chemotherapy. The study's primary endpoint is overall survival, and Aduro hopes it'll back up the safety, immune response and efficacy CRS-207 and GVAX have demonstrated thus far.

Aduro is one of the few small biotechs in the cancer field to win a breakthrough drug designation from the FDA. The BTD is designed to grease the regulatory skids for promising new therapies.

"We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer," said Stephen Isaacs, chairman, president and chief executive officer of Aduro. "Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."

谢谢楼主，辛苦了